Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy.

In diabetic patients, an early index of peripheral neuropathy is the slowing of conduction velocity in large myelinated neurons and a lack of understanding of the basic pathogenic mechanisms hindered therapeutics development. Racemic (R/S)-guaifenesin (1) was identified as a potent enhancer of neurite outgrowth using an in vitro screen. Its R-enantiomer (R)-1 carried the most biological activity, whereas the S-enantiomer (S)-1 was inactive. Focused structural variations to (R/S)-1 was conducted to identify potentially essential groups for the neurite outgrowth activity. In vivo therapeutic studies indicated that both (R/S)-1 and (R)-1 partially prevented motor nerve conduction velocity slowing in a mouse model of type 1 diabetes. In vitro microsomal assays suggested that compounds (R)-1 and (S)-1 are not metabolized rapidly, and PAMPA assay indicated moderate permeability through the membrane. Findings revealed here could lead to the development of novel drugs for diabetic neuropathy.

Citation

Mallinath B Hadimani, Meena K Purohit, Chandrashaker Vanampally, Randy Van der Ploeg, Victor Arballo, Dwane Morrow, Katie E Frizzi, Nigel A Calcutt, Paul Fernyhough, Lakshmi P Kotra. Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. Journal of medicinal chemistry. 2013 Jun 27;56(12):5071-8

Mesh Tags

Substances

PMID: 23758573

search → result